Individual results may vary

"Alnylam Assist®, and our Case
Manager, really helped us navigate
the approval process."
—Amalia, patient with AIP

Individual results may vary

"Alnylam Assist®, and our Case
Manager, really helped us navigate
the approval process."
—Amalia, patient with AIP

Dedicated support every step of the way
with Alnylam Assist®

As you begin your treatment with GIVLAARI® (givosiran), Alnylam Assist® will provide you with a dedicated Alnylam Case Manager and Alnylam Patient Education Liaison (PEL) for ongoing support throughout treatment. Once you and your healthcare provider choose to begin treatment, you should complete a Start Form together and submit it to Alnylam Assist®.

Upon receipt of the Start Form, an Alnylam Case Manager dedicated to your needs will reach out to you within 2 business days and will provide ongoing support throughout treatment. Alnylam Assist® support includes:

Understanding your insurance benefits

Navigating your insurance benefits

We will review your insurance coverage and answer questions about your insurance benefits for GIVLAARI.

Ongoing support

A dedicated support team

Whether you have questions about navigating insurance, getting started on treatment, or locating additional resources for people with acute hepatic porphyria (AHP), there is a dedicated team ready to help. Call Alnylam Assist® to speak to your Case Manager or PEL to learn more.

Financial assistance

Financial assistance

Alnylam is committed to making GIVLAARI available to those who need it. When you and your healthcare provider decide to start treatment, your Case Manager will work with you to determine eligibility for Alnylam's financial assistance programs.* 

  • If you have commercial insurance, our Copay Program offers assistance with drug-related out-of-pocket expenses—including copays and co-insurance—regardless of your financial status
  • If you do not have insurance, or are unable to pay for treatment, our Patient Assistance Program may be able to provide you with GIVLAARI at no cost
  • Talk to your Case Manager to learn more about Alnylam financial assistance program eligibility

*Individuals must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for Alnylam's Commercial Copay Program.

For more information about Alnylam Assist® or to access downloadable materials:

Alnylam Assist® logo
Contact Info


Call: 1-833-256-2748

Monday-Friday, 8 AM-6 PM ET

Partner with your dedicated support team

A dedicated Alnylam Case Manager

When you and your healthcare provider choose to begin treatment with GIVLAARI, you will be partnered with a dedicated Alnylam Case Manager. Case Managers are experienced in helping individuals get started on treatment and providing ongoing support. They will tailor their level of contact based on your personal needs.

Check mark Helping you get started on treatment
Check mark Providing you with personalized support
Check mark Navigating your insurance benefits
Check mark Determining your eligibility for financial assistance

A dedicated Alnylam Patient Education Liaison (PEL)

Our Patient Education Liaisons have backgrounds in nursing and are experienced in educating people and their families about matters related to AHP. Your PEL can help you in a variety of ways, such as:

Check mark Supporting you with disease education
Check mark Connecting you to additional resources
Check mark Answering questions about treatment

The purpose of the Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers. PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team. PELs do not provide medical care or advice. All diagnosis and treatment decisions should be made by you and your doctor.



Do not use GIVLAARI if you have ever had a severe allergic reaction to GIVLAARI.

  • Tell your doctor or nurse right away if you experience any of the following signs or symptoms of a severe allergic reaction during treatment:

    • Swelling – mainly of the lips, tongue or throat which makes it difficult to swallow or breathe
    • Breathing problems or wheezing
    • Feeling dizzy or fainting
    • Rash or hives
    • Itching

    If you have a severe allergic reaction, your doctor or nurse will stop GIVLAARI treatment right away and you may need to take other medicines to control the symptoms.

  • Your doctor will check your liver function by doing blood tests:

    • Before you start using GIVLAARI
    • Once a month for the first 6 months of treatment
    • And when they think it is needed

    If these tests show abnormal results, your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

  • Your doctor will check how your kidneys are working while you are using GIVLAARI.

  • GIVLAARI is given as an injection under the skin (called a “subcutaneous injection”). Reactions to this injection may happen during treatment with GIVLAARI.

    Tell your doctor or nurse right away if you experience any of the following symptoms of an injection site reaction during treatment: redness, pain, itchiness, rash, discoloration, or swelling around the injection site.

  • GIVLAARI may cause increased levels of homocysteine (a type of amino acid) in your blood. Your doctor will check your homocysteine levels before and during treatment by doing blood tests. If your levels are increased, your doctor may check your folate, vitamins B12 and B6, and tell you to take a vitamin B6 supplement.

The most common side effects of GIVLAARI are nausea and injection site reactions. These are not all the possible side effects of GIVLAARI. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-8 00-FDA -1088.

WHAT IS GIVLAARI® (givosiran)?

GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults.

For additional information about GIVLAARI, please see full Prescribing Information.